As it recapitulates the diversity of NF1 symptoms, the Prss56-Nf1 KO mouse model is also a promising pre-clinical model to test pharmacological approaches for NF1 neurofibromas and bone manifestations.27,36 Strategies to treat NF1 symptoms mainly target the hyperactivity of RAS-MAPK pathways. The gene discussed is PRSS56; the disease is plexiform neurofibroma.